492 related articles for article (PubMed ID: 17652028)
1. Progress towards an AIDS mucosal vaccine: an overview.
Yuki Y; Nochi T; Kiyono H
Tuberculosis (Edinb); 2007 Aug; 87 Suppl 1():S35-44. PubMed ID: 17652028
[TBL] [Abstract][Full Text] [Related]
2. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
Belyakov IM; Ahlers JD
Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
[TBL] [Abstract][Full Text] [Related]
3. New horizon of mucosal immunity and vaccines.
Takahashi I; Nochi T; Yuki Y; Kiyono H
Curr Opin Immunol; 2009 Jun; 21(3):352-8. PubMed ID: 19493665
[TBL] [Abstract][Full Text] [Related]
4. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
[TBL] [Abstract][Full Text] [Related]
5. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
[TBL] [Abstract][Full Text] [Related]
6. In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens.
McGhee JR; Mestecky J
Infect Dis Clin North Am; 1990 Jun; 4(2):315-41. PubMed ID: 2189002
[TBL] [Abstract][Full Text] [Related]
7. New perspectives in vaccine development: mucosal immunity to infections.
McGhee JR; Kiyono H
Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356
[TBL] [Abstract][Full Text] [Related]
8. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
[TBL] [Abstract][Full Text] [Related]
9. Progress and obstacles in the development of an AIDS vaccine.
Letvin NL
Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
[TBL] [Abstract][Full Text] [Related]
10. The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12.
Belyakov IM; Ahlers JD; Brandwein BY; Earl P; Kelsall BL; Moss B; Strober W; Berzofsky JA
J Clin Invest; 1998 Dec; 102(12):2072-81. PubMed ID: 9854042
[TBL] [Abstract][Full Text] [Related]
11. Mucosal immune dysfunction in AIDS pathogenesis.
Paiardini M; Frank I; Pandrea I; Apetrei C; Silvestri G
AIDS Rev; 2008; 10(1):36-46. PubMed ID: 18385779
[TBL] [Abstract][Full Text] [Related]
12. Mucosal immunity, HIV transmission, and AIDS.
Miller CJ; McGhee JR; Gardner MB
Lab Invest; 1993 Feb; 68(2):129-45. PubMed ID: 8441249
[No Abstract] [Full Text] [Related]
13. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.
Belyakov IM; Ahlers JD
Curr Top Microbiol Immunol; 2012; 354():157-79. PubMed ID: 21203884
[TBL] [Abstract][Full Text] [Related]
14. Virus-like particles as HIV-1 vaccines.
Doan LX; Li M; Chen C; Yao Q
Rev Med Virol; 2005; 15(2):75-88. PubMed ID: 15484204
[TBL] [Abstract][Full Text] [Related]
15. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
Hinkula J
Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
[TBL] [Abstract][Full Text] [Related]
16. Rethinking globally relevant vaccine strategies to human immunodeficiency virus type-1.
Gray CM; Puren AJ
Arch Immunol Ther Exp (Warsz); 2000; 48(4):235-41. PubMed ID: 11059639
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
Johnson DC; McFarland EJ; Muresan P; Fenton T; McNamara J; Read JS; Hawkins E; Bouquin PL; Estep SG; Tomaras GD; Vincent CA; Rathore M; Melvin AJ; Gurunathan S; Lambert J
J Infect Dis; 2005 Dec; 192(12):2129-33. PubMed ID: 16288378
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.
Belyakov IM; Ahlers JD
Curr Med Chem; 2011; 18(26):3953-62. PubMed ID: 21824096
[TBL] [Abstract][Full Text] [Related]
19. AIDS vaccine development: the long and winding road.
Garber DA; Feinberg MB
AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
[TBL] [Abstract][Full Text] [Related]
20. HIV CTL escape: at what cost?
Smith SM
Retrovirology; 2004 May; 1():8. PubMed ID: 15169568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
